All In MedTech

FDA Clearance Tracker · K173248

CARDIOSKIN

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 20, 2026Latest source record: Aug 11, 2018 (this decision)Source: openFDAMethods & limitations

510(k)

Decided

Aug 11, 2018

Substantially Equivalent

Time to decision

305 days

Received Oct 10, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Traditional

Device class

Class II

The decision

FDA number
K173248
Device name
CARDIOSKIN
Applicant location
Paris, FR
Received
Oct 10, 2017
Decided
Aug 11, 2018
Decision
Substantially Equivalent
Submission type
Traditional

Device type

Device class
Class II
Regulation
21 CFR 870.2920

Every decision under product code DXH

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code DXH. The earliest in FDA's data is K760564, decided Sep 10, 1976.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Bioserenity Sas

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.